Survival outcomes of obese patients in type II endometrial cancer: Defining the prognostic impact of increasing BMI

Caroline C. Billingsley, Catherine D Cansino, David M. O'Malley, David E. Cohn, Jeffrey M. Fowler, Larry J. Copeland, Floor J. Backes, Ritu Salani

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Objective To investigate the role of obesity as a risk factor for type II endometrial cancer (EC), as well as the prognostic significance of increasing body mass index (BMI) on survival. Methods A single institution retrospective analysis of 154 type II EC cases from 1987 to 2010 was conducted. Patients were categorized into cohorts by BMI (normal (< 25), overweight (25-29.9), obese class I (30-34.9), and obese class II-III (≥ 35)). Descriptive, regression and ANOVA analyses were performed. Kaplan-Meier curves were compared with log rank tests. Results The BMI distribution was 22.8% normal BMI; 24% overweight; 17.5% class I; and 35.7% class II-III. The median follow up was 41 months. The median progression-free survival (PFS) was 45.4, 36.0, 35.3 and 42.0 months and overall survival (OS) was 54.7, 44.7, 44.8 and 49.7 months, among the respective groups. There was no association between BMI and PFS (p = 0.71), OS (p = 0.72), or time to recurrence (p = 0.71). There were no differences among the increasing BMI groups compared to normal weight women for the risk of death. Conclusions Our analysis did not reveal any differences in outcomes by BMI group. Our data reveals that obesity is highly prevalent in type II ECs, though obesity has not historically been described as a risk factor. While BMI as a single variable may not be prognostic for survival outcomes, the role of obesity as a risk factor for type II EC should be further investigated, given the increasing prevalence of obesity in type II ECs.

Original languageEnglish (US)
Pages (from-to)405-408
Number of pages4
JournalGynecologic Oncology
Volume140
Issue number3
DOIs
StatePublished - Mar 1 2016

Fingerprint

Endometrial Neoplasms
Body Mass Index
Survival
Obesity
Disease-Free Survival
Analysis of Variance
Regression Analysis
Weights and Measures
Recurrence

Keywords

  • Endometrial cancer
  • Obesity
  • Survival outcomes
  • Type II

ASJC Scopus subject areas

  • Medicine(all)
  • Oncology
  • Obstetrics and Gynecology

Cite this

Survival outcomes of obese patients in type II endometrial cancer : Defining the prognostic impact of increasing BMI. / Billingsley, Caroline C.; Cansino, Catherine D; O'Malley, David M.; Cohn, David E.; Fowler, Jeffrey M.; Copeland, Larry J.; Backes, Floor J.; Salani, Ritu.

In: Gynecologic Oncology, Vol. 140, No. 3, 01.03.2016, p. 405-408.

Research output: Contribution to journalArticle

Billingsley, CC, Cansino, CD, O'Malley, DM, Cohn, DE, Fowler, JM, Copeland, LJ, Backes, FJ & Salani, R 2016, 'Survival outcomes of obese patients in type II endometrial cancer: Defining the prognostic impact of increasing BMI', Gynecologic Oncology, vol. 140, no. 3, pp. 405-408. https://doi.org/10.1016/j.ygyno.2016.01.020
Billingsley, Caroline C. ; Cansino, Catherine D ; O'Malley, David M. ; Cohn, David E. ; Fowler, Jeffrey M. ; Copeland, Larry J. ; Backes, Floor J. ; Salani, Ritu. / Survival outcomes of obese patients in type II endometrial cancer : Defining the prognostic impact of increasing BMI. In: Gynecologic Oncology. 2016 ; Vol. 140, No. 3. pp. 405-408.
@article{14b939ee472f44afae8679dc846cc974,
title = "Survival outcomes of obese patients in type II endometrial cancer: Defining the prognostic impact of increasing BMI",
abstract = "Objective To investigate the role of obesity as a risk factor for type II endometrial cancer (EC), as well as the prognostic significance of increasing body mass index (BMI) on survival. Methods A single institution retrospective analysis of 154 type II EC cases from 1987 to 2010 was conducted. Patients were categorized into cohorts by BMI (normal (< 25), overweight (25-29.9), obese class I (30-34.9), and obese class II-III (≥ 35)). Descriptive, regression and ANOVA analyses were performed. Kaplan-Meier curves were compared with log rank tests. Results The BMI distribution was 22.8{\%} normal BMI; 24{\%} overweight; 17.5{\%} class I; and 35.7{\%} class II-III. The median follow up was 41 months. The median progression-free survival (PFS) was 45.4, 36.0, 35.3 and 42.0 months and overall survival (OS) was 54.7, 44.7, 44.8 and 49.7 months, among the respective groups. There was no association between BMI and PFS (p = 0.71), OS (p = 0.72), or time to recurrence (p = 0.71). There were no differences among the increasing BMI groups compared to normal weight women for the risk of death. Conclusions Our analysis did not reveal any differences in outcomes by BMI group. Our data reveals that obesity is highly prevalent in type II ECs, though obesity has not historically been described as a risk factor. While BMI as a single variable may not be prognostic for survival outcomes, the role of obesity as a risk factor for type II EC should be further investigated, given the increasing prevalence of obesity in type II ECs.",
keywords = "Endometrial cancer, Obesity, Survival outcomes, Type II",
author = "Billingsley, {Caroline C.} and Cansino, {Catherine D} and O'Malley, {David M.} and Cohn, {David E.} and Fowler, {Jeffrey M.} and Copeland, {Larry J.} and Backes, {Floor J.} and Ritu Salani",
year = "2016",
month = "3",
day = "1",
doi = "10.1016/j.ygyno.2016.01.020",
language = "English (US)",
volume = "140",
pages = "405--408",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "3",

}

TY - JOUR

T1 - Survival outcomes of obese patients in type II endometrial cancer

T2 - Defining the prognostic impact of increasing BMI

AU - Billingsley, Caroline C.

AU - Cansino, Catherine D

AU - O'Malley, David M.

AU - Cohn, David E.

AU - Fowler, Jeffrey M.

AU - Copeland, Larry J.

AU - Backes, Floor J.

AU - Salani, Ritu

PY - 2016/3/1

Y1 - 2016/3/1

N2 - Objective To investigate the role of obesity as a risk factor for type II endometrial cancer (EC), as well as the prognostic significance of increasing body mass index (BMI) on survival. Methods A single institution retrospective analysis of 154 type II EC cases from 1987 to 2010 was conducted. Patients were categorized into cohorts by BMI (normal (< 25), overweight (25-29.9), obese class I (30-34.9), and obese class II-III (≥ 35)). Descriptive, regression and ANOVA analyses were performed. Kaplan-Meier curves were compared with log rank tests. Results The BMI distribution was 22.8% normal BMI; 24% overweight; 17.5% class I; and 35.7% class II-III. The median follow up was 41 months. The median progression-free survival (PFS) was 45.4, 36.0, 35.3 and 42.0 months and overall survival (OS) was 54.7, 44.7, 44.8 and 49.7 months, among the respective groups. There was no association between BMI and PFS (p = 0.71), OS (p = 0.72), or time to recurrence (p = 0.71). There were no differences among the increasing BMI groups compared to normal weight women for the risk of death. Conclusions Our analysis did not reveal any differences in outcomes by BMI group. Our data reveals that obesity is highly prevalent in type II ECs, though obesity has not historically been described as a risk factor. While BMI as a single variable may not be prognostic for survival outcomes, the role of obesity as a risk factor for type II EC should be further investigated, given the increasing prevalence of obesity in type II ECs.

AB - Objective To investigate the role of obesity as a risk factor for type II endometrial cancer (EC), as well as the prognostic significance of increasing body mass index (BMI) on survival. Methods A single institution retrospective analysis of 154 type II EC cases from 1987 to 2010 was conducted. Patients were categorized into cohorts by BMI (normal (< 25), overweight (25-29.9), obese class I (30-34.9), and obese class II-III (≥ 35)). Descriptive, regression and ANOVA analyses were performed. Kaplan-Meier curves were compared with log rank tests. Results The BMI distribution was 22.8% normal BMI; 24% overweight; 17.5% class I; and 35.7% class II-III. The median follow up was 41 months. The median progression-free survival (PFS) was 45.4, 36.0, 35.3 and 42.0 months and overall survival (OS) was 54.7, 44.7, 44.8 and 49.7 months, among the respective groups. There was no association between BMI and PFS (p = 0.71), OS (p = 0.72), or time to recurrence (p = 0.71). There were no differences among the increasing BMI groups compared to normal weight women for the risk of death. Conclusions Our analysis did not reveal any differences in outcomes by BMI group. Our data reveals that obesity is highly prevalent in type II ECs, though obesity has not historically been described as a risk factor. While BMI as a single variable may not be prognostic for survival outcomes, the role of obesity as a risk factor for type II EC should be further investigated, given the increasing prevalence of obesity in type II ECs.

KW - Endometrial cancer

KW - Obesity

KW - Survival outcomes

KW - Type II

UR - http://www.scopus.com/inward/record.url?scp=84959483794&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84959483794&partnerID=8YFLogxK

U2 - 10.1016/j.ygyno.2016.01.020

DO - 10.1016/j.ygyno.2016.01.020

M3 - Article

C2 - 26801939

AN - SCOPUS:84959483794

VL - 140

SP - 405

EP - 408

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 3

ER -